Torquil Watt

Torquil Watt

Auto-generated profile, based on publicly available information

Torquil Watt

Copenhagen University Hospital Rigshospitalet

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2017 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
DSDavid J. Stott
David J. Stott
NRNicolas Rodondi
Nicolas Rodondi
PKPatricia M. Kearney
Patricia M. Kearney
IFIan Ford
Ian Ford
RWRudi G.J. Westendorp
Rudi G.J. Westendorp
JGJacobijn Gussekloo
Jacobijn Gussekloo
The use of levothyroxine to treat subclinical hypothyroidism is controversial. We aimed to determine whether levothyroxine provided clinical benefits in older persons with this condition. We conducted a double-blind, randomized, placebo-controlled, parallel-group trial involving 737 adults who were at least 65 years of age and who had persisting subclinical hypothyroidism (thyrotropin level, 4.60 to 19.99 mIU per liter; free thyroxine level within the reference range). A total of 368 patients were assigned to receive levothyroxine (at a starting dose of 50 μg daily, or 25 μg if the body weight was <50 kg or the patient had coronary heart disease), with dose adjustment according to the thyrotropin level; 369 patients were assigned to receive placebo with mock dose adjustment. The two primary outcomes were the change in the Hypothyroid Symptoms score and Tiredness score on a thyroid-related quality-of-life questionnaire at 1 year (range of each scale is 0 to 100, with higher scores indicating more symptoms or tiredness, respectively; minimum clinically important difference, 9 points). The mean age of the patients was 74.4 years, and 396 patients (53.7%) were women. The mean (±SD) thyrotropin level was 6.40±2.01 mIU per liter at baseline; at 1 year, this level had decreased to 5.48 mIU per liter in the placebo group, as compared with 3.63 mIU per liter in the levothyroxine group (P<0.001), at a median dose of 50 μg. We found no differences in the mean change at 1 year in the Hypothyroid Symptoms score (0.2±15.3 in the placebo group and 0.2±14.4 in the levothyroxine group; between-group difference, 0.0; 95% confidence interval [CI], −2.0 to 2.1) or the Tiredness score (3.2±17.7 and 3.8±18.4, respectively; between-group difference, 0.4; 95% CI, −2.1 to 2.9). No beneficial effects of levothyroxine were seen on secondary-outcome measures. There was no significant excess of serious adverse events prespecified as being of special interest. Levothyroxine provided no apparent benefits in older persons with subclinical hypothyroidism. (Funded by European Union FP7 and others; TRUST ClinicalTrials.gov number, NCT01660126.)

1 November 1998 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
JBJakob B. Bjorner
Jakob B. Bjorner
MDMogens T. Damsgaard
Mogens T. Damsgaard
TWTorquil Watt
Torquil Watt
MGMogens Groenvold
Mogens Groenvold

1 January 2010 in European Journal of Endocrinology
Verified
Journal Article
Closed access
TWTorquil Watt
Torquil Watt
LHLaszlo Hegedüs
Laszlo Hegedüs
MGMogens Groenvold
Mogens Groenvold
JBJakob Bue Bjorner
Jakob Bue Bjorner
ÅRÅse Krogh Rasmussen
Åse Krogh Rasmussen
UFUlla Feldt-Rasmussen
Ulla Feldt-Rasmussen
Background: Appropriate scale validity and internal consistency reliability have recently been documented for the new thyroid-specific quality of life (QoL) patient-reported outcome (PRO) measure for benign thyroid disorders, the ThyPRO. However, before clinical use, clinical validity and test–retest reliability should be evaluated.Aim: To investigate clinical (‘known-groups’) validity and test–retest reliability of the Danish version of the ThyPRO.Methods: For each of the 13 ThyPRO scales, we defined groups expected to have high versus low scores (‘known-groups’). The clinical validity (known-groups validity) was evaluated by whether the ThyPRO scales could detect expected differences in a cross-sectional study of 907 thyroid patients. Test–retest reliability was evaluated by intra-class correlations of two responses to the ThyPRO 2 weeks apart in a subsample of 87 stable patients.Results: On all 13 ThyPRO scales, we found substantial and significant differences between the groups expected to have high versus low scores. Test–retest reliability was above 0.70 (range 0.77–0.89) for all scales, which is usually considered necessary for comparisons among patient groups, but below 0.90, which is the usual threshold for use in individual patients.Conclusion: We found support for the clinical validity of the new thyroid-specific QoL questionnaire, ThyPRO, and evidence of good test–retest reliability. The questionnaire is now ready for use in clinical studies of patients with thyroid diseases.

1 November 2000 in Journal of Epidemiology and Community Health
Verified
Journal Article
Open access
PDF file
TWTorquil Watt
Torquil Watt
MGMogens Groenvold
Mogens Groenvold
JBJakob Bue Bjorner
Jakob Bue Bjorner
VNVibeke Noerholm
Vibeke Noerholm
NRNiels-Anton Rasmussen
Niels-Anton Rasmussen
PBPer Bech
Per Bech
OBJECTIVE To measure the levels of fatigue in the general population, and to examine how disease and sociodemographic factors influence fatigue. DESIGN Cross sectional questionnaire study in the Danish general population. SUBJECTS A random, age stratified sample of 1608 people aged 20–77 with an equal gender distribution (response rate 67%). MAIN OUTCOME MEASURES Five fatigue scales from the questionnaire Multidimensional Fatigue Inventory: General Fatigue, Physical Fatigue, Reduced Activity, Reduced Motivation and Mental Fatigue. RESULTS Fatigue scores were skewed towards absence of fatigue. The General Fatigue and Physical Fatigue scales showed the highest fatigue levels while the Reduced Motivation scale showed lowest levels. Gender differences in fatigue scores were small, but the variability among women was higher—that is, more women had high scores. A multiple linear regression analysis showed that respondents of low social status and respondents with a depression had high fatigue scores on all scales, independent of other factors. Chronic somatic disease had an independent direct effect on Mental Fatigue, but for the rest of the scales, the effect of somatic disease depended on age, gender and/or whether the person was living alone. For example, General and Physical Fatigue decreased with age among healthy people, whereas scores on these scales increased with age among those with a somatic disease. CONCLUSIONS Physical and mental diseases play essential parts for the level of fatigue and as modulators of the associations between sociodemographic factors and fatigue. These interactions should be taken into account in future research on fatigue and sociodemographic factors and when data from clinical studies are compared with normative data from the general population.

1 April 2006 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
TWTorquil Watt
Torquil Watt
MGMogens Groenvold
Mogens Groenvold
ARÅsE Krogh Rasmussen
ÅsE Krogh Rasmussen
SBSteen Joop Bonnema
Steen Joop Bonnema
LHLaszlo Hegedüs
Laszlo Hegedüs
UFUlla Feldt-Rasmussen
Ulla Feldt-Rasmussen
The importance of patient-reported outcomes such as health-related quality of life (HRQL) in clinical research is increasingly acknowledged. In order to yield valid results, the measurement properties of HRQL questionnaires must be thoroughly investigated. One aspect of such a validation process is the demonstration of content validity, i.e. that the questionnaire covers all relevant aspects. We review studies reporting on consequences of thyroid disorders and present the frequency of identified aspects, both overall HRQL issues and classical thyroid symptoms, in order to evaluate which issues are relevant for patients with thyroid diseases. Furthermore, existing questionnaires for thyroid patients are reviewed. A systematic search was performed in the Medline, Cinahl and Psycinfo databases and the reference lists of the relevant articles were hand-searched. Seventy-five relevant studies were identified. According to these studies, patients with untreated thyroid disease suffer from a wide range of symptoms and have major impairment in most areas of HRQL. Furthermore, the studies indicate that impairments in HRQL are also frequent in the long term. Six HRQL questionnaires for thyroid patients were identified. Generally, data supporting the validity of these questionnaires were sparse. According to the available literature, the quality of life of thyroid patients is substantially impaired over a wide range of aspects of HRQL in the untreated phase and continues to be so in many patients also in the long term. Studies systematically exploring the relative importance of these various aspects to thyroid patients are lacking, as is a comprehensive, validated thyroid-specific HRQL questionnaire.

17 June 2008 in Cerebrovascular Diseases
Verified
Journal Article
Closed access
DCDoris Christensen
Doris Christensen
SJSoeren Paaske Johnsen
Soeren Paaske Johnsen
TWTorquil Watt
Torquil Watt
IHIngegerd Harder
Ingegerd Harder
MKMarit Kirkevold
Marit Kirkevold
GAGrethe Andersen
Grethe Andersen
Background: The aim of this study was to examine the course of poststroke fatigue in a cohort of first-time stroke patients compared to the general population, and to identify clinically relevant features of post-stroke fatigue. Methods: We performed a follow-up study of 165 patients with first-time stroke admitted to acute stroke units at the Aarhus University Hospital, Denmark. A reference group of 1,069 persons was sampled from the general population. Fatigue was assessed using the Multidimensional Fatigue Inventory (MFI-20) covering five scales of fatigue (General Fatigue, Physical Fatigue, Reduced Activity, Reduced Motivation, and Mental Fatigue). Results: Compared to the general population, stroke patients reported higher levels of Physical Fatigue. Minor or no differences were found for the other fatigue scales. Pathological fatigue, defined as a score ≧12 on the General Fatigue scale, was reported by 59% (95% CI: 51–66%), 44% (95% CI: 36–51%), 38% (95% CI: 31–46%), and 40% (95% CI: 32–48%) of stroke patients 10 days, 3 months, 1 year, and 2 years following hospitalization for stroke, respectively. Post-stroke fatigue levels decreased after three months and remained stable throughout the remainder of follow-up. Poor functional outcome was consistently associated with increased levels of fatigue. Conclusions: Post-stroke fatigue is a common condition primarily characterized by increased levels of Physical Fatigue. The pathological mechanisms underlying post-stroke fatigue and its clinical implications require further study.